



science and policy
for a healthy future

HBM4EU project

Communication of HBM results to
groups and individuals

Paul T.J. Scheepers PhD

Task leader WP2.5 training

Contents

Communication of HBM results

1. Communication plan
2. At a Group and individual level
3. What is the content of the message?



- A communication plan should be ready **before** starting the HBM campaign
- The communication procedures and materials should be made available when the study protocol is evaluated for **ethics approval**
- Note that children should be able to **opt out** when they turn 18.
- The informed consent should cover the **broader use of data** in the context of HBM4EU, including use of HBM data for IPCHEM.



- Explain **how and when** the results of the study will be made available
- Results **on a group level** should be communicated without explicit information that might point to an individual by name, street address or any other (indirect source of) information.
- Who will be the **sender**? Who is the **receiving** party (e.g. in the case of adolescents)
- Be aware that in small groups individuals may still be(come) **identifiable** (indirectly by a combinations of certain characteristics)

- Even if you are reporting on biomarkers of exposure (only) many subjects may still **perceive** a lab result as health-related information.
- Any outcome may have **more impact** if the study subject is a child or otherwise vulnerable individual
- Be prepared to refer a study participant to a physician if there are questions related to the **personal/medical situation**, e.g. concerning pregnancy.

HEALTH CARE



- Confirm what is **already known** and also address any **questionable information** is released through social media, e.g. regarding:
 - Hazard classification of a chemical
 - Interpretation of risk level that is unrealistic
- What **context** is available for reporting of the biomarker of interest:
 - Background in the population as a reference
 - Guidance values for the general population
 - Guidance values for the worker's population
- Do not be afraid to address the fact that there is **uncertainty** or even a **gap in knowledge**

- What are the possible causes and consequences of an enhanced biomarker outcome?
- What can the subject himself/herself do about it? Also if nothing can be done about it, this should be highlighted.
- Address the problem that an individual outcome cannot be translated to a risk.
- Only in limited cases a group level could be put in perspective if the group can (to some extent) be compared to a population that was earlier studied in a sound epidemiological design

Use Supporting information such as

- Graphic
- Animation
- Video message
- Podcast



What are the proper channels to communicate

- Personalized **written information**
- Closed **group meeting** (for participants only)
- Refer to the possibility of an **individual consultation** as an add-on if this should be needed, also at a later stage (e.g. for participating children)




- It is a good practice to involve an **independent physician** available to discuss concerns that the subject (or his/her parent/caretaker) does not want to discuss with the researcher. This physician should accept to take this role and be well-informed about the study.



- Consider to ask the subject if he/she wants to have access to **his/her own data** as part of the informed consent.
- Consider to ask the subject if he/she agrees that individual HBM data are made **available to the general practitioner**
- Note that a finding may be(come) relevant if it indicates a health problem such as a too high urinary creatinine as an indication of kidney damage. You need the **consent** of the study subject if you want to inform the subject's physician.

- Would be good to think over a scenario where individuals have (expectedly or unexpectedly) a **higher value**.
- What if the individual result is an **outlier**. Is there a contingency plan, e.g. an offer to repeat collect and analyse a follow-up sample.



Take home

Good to agree on a **communication plan** from the start

Define the communication **process** and the **message** for each scenario

Do not be afraid to name **uncertainties** and **unknowns**

Provide additional **personal counselling** if needed

Contacts

paul.scheepers@radboudumc.nl

HBM4EUtraining.hev@radboudumc.nl

Speaker's information

Paul T.J. Scheepers PhD works as associate professor at the Radboudumc, Nijmegen, The Netherlands. He received training in toxicology and occupational hygiene. In HBM4EU he is responsible for training activities as task leader in WP2. He is a member of the ethics board in WP1.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733032.